Literature DB >> 12458399

Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET.

Marc Hickeson1, Mijin Yun, Alexander Matthies, Hongming Zhuang, Lars-Eric Adam, Lester Lacorte, Abass Alavi.   

Abstract

The purpose of this study was to determine the actual standardized uptake value (SUV) by using the lesion size from computer tomography (CT) scan to correct for resolution and partial volume effects in positron emission tomography (PET) imaging. This retrospective study included 47 patients with lung lesions seen on CT scan whose diagnoses were confirmed by biopsy or by follow up CT scan when the PET result was considered negative for malignancy. Each lesion's FDG uptake was quantified by the SUV using two methods: by measuring the maximum voxel SUV (maxSUV) and by using the lesion's size on CT to calculate the actual SUV (corSUV). Among small lesions (2.0 cm or smaller on CT scan), ten were benign and 17 were malignant. The average maxSUV was 1.43+/-0.77 and 3.02+/-1.74 for benign and malignant lesions respectively. When using an SUV of 2.0 as the cutoff to differentiate benignity and malignancy, the sensitivity, specificity, and accuracy were 65%, 70%, and 67% respectively. When an SUV of 2.5 was used for cutoff, the sensitivity, specificity, and accuracy were 47%, 80%, and 59% respectively. The average corSUV was 1.65+/-1.09 and 5.28+/-2.71 for benign and malignant lesions respectively. Whether an SUV of either 2.0 or 2.5 was used for cutoff, the sensitivity, specificity, and accuracy remained 94%, 70%, and 85% respectively. The only malignant lesion that was falsely considered benign with both methods was a bronchioalveolar carcinoma which did not reveal any elevated uptake of fluorine-18 fluorodeoxyglucose (FDG). Of the large lesions (more than 2.0 cm and less than 6.0 cm), one was benign and 19 were malignant and the corSUV technique did not significantly change the accuracy. It is concluded that measuring the SUV by using the CT size to correct for resolution and partial volume effects offers potential value in differentiating malignant from benign lesions in this population. This approach appears to improve the accuracy of FDG-PET for optimal characterization of small lung nodules.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12458399     DOI: 10.1007/s00259-002-0924-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  50 in total

1.  Measurement of SUVmax plus ADCmin of the primary tumour is a predictor of prognosis in patients with cervical cancer.

Authors:  Keiichiro Nakamura; Ikuo Joja; Junichi Kodama; Atsushi Hongo; Yuji Hiramatsu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-10       Impact factor: 9.236

2.  Amyloid-β imaging with PET in Alzheimer's disease: is it feasible with current radiotracers and technologies?

Authors:  Mateen C Moghbel; Babak Saboury; Sandip Basu; Scott D Metzler; Drew A Torigian; Bengt Långström; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

3.  Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer.

Authors:  Wenfeng Yang; Yongming Zhang; Zheng Fu; Jinming Yu; Xiaorong Sun; Dianbin Mu; Anqin Han
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-23       Impact factor: 9.236

4.  Comments on characterization of solitary pulmonary nodules with 18F-FDG PET/CT relative activity distribution analysis.

Authors:  Orazio Schillaci; Ferdinando F Calabria
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

5.  SUVmax of 2.5 should not be embraced as a magic threshold for separating benign from malignant lesions.

Authors:  Thomas C Kwee; Gang Cheng; Marnix G E H Lam; Sandip Basu; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10       Impact factor: 9.236

6.  Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: should these be routinely employed in assessing patients with cancer?

Authors:  Sandip Basu; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10       Impact factor: 9.236

7.  Imaging proliferation of ¹⁸F-FLT PET/CT correlated with the expression of microvessel density of tumour tissue in non-small-cell lung cancer.

Authors:  Wenfeng Yang; Yongming Zhang; Zheng Fu; Xiaorong Sun; Dianbin Mu; Jinming Yu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-05-12       Impact factor: 9.236

8.  Characterization of solitary pulmonary nodules with 18F-FDG PET/CT relative activity distribution analysis.

Authors:  Liang Zhao; Li Tong; Jie Lin; Kun Tang; SiSi Zheng; WenFeng Li; DeZhi Cheng; WeiWei Yin; XiangWu Zheng
Journal:  Eur Radiol       Date:  2015-02-01       Impact factor: 5.315

9.  [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy.

Authors:  Alina Berriolo-Riedinger; Claude Touzery; Jean-Marc Riedinger; Michel Toubeau; Bruno Coudert; Laurent Arnould; Christophe Boichot; Alexandre Cochet; Pierre Fumoleau; François Brunotte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06-20       Impact factor: 9.236

10.  Partial volume correction strategies for quantitative FDG PET in oncology.

Authors:  Nikie J Hoetjes; Floris H P van Velden; Otto S Hoekstra; Corneline J Hoekstra; Nanda C Krak; Adriaan A Lammertsma; Ronald Boellaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-04-27       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.